Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.